Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety

Exclusion Criteria

• •Prior treatment with non-liposomal amphotericin B formulations (e.g., amphotericin B deoxycholate) for ≥4 days.
• •Documented hypersensitivity, severe immediate allergic reaction, or intolerance to liposomal amphotericin B.
• •History of a second malignancy (other than the index hematologic malignancy) treated within the past 3 years.
• •Active HIV infection, hepatitis B virus (HBV) infection (HBsAg-positive), hepatitis C virus (HCV) infection (RNA-positive), or syphilis.
• •Psychiatric disorders, cognitive impairment, or other conditions impairing compliance with study procedures or assessments.
• •Pregnant females, breastfeeding females, or individuals of reproductive potential unwilling to use effective contraception during treatment and for ≥3 months post-therapy.
• •Serum creatinine ≥2.0 × upper limit of normal (ULN).
• •Liver transaminases (ALT/AST) or alkaline phosphatase ≥5.0 × ULN.
• •Total bilirubin ≥3.0 × ULN (isolated bilirubin ≥3.0 × ULN is permitted if due to Gilbert's syndrome or hemolysis).
• •Patients deemed ineligible by the investigator due to medical, ethical, or logistical reasons.